FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks

United States News News

FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
United States Latest News,United States Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 56 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 72%

Maker of promising Alzheimer’s drug Leqembi expects full FDA approval this summer, expanded Medicare coverage Symptoms can range from brief weakness to paralysis.

Most patients, even those with severe cases, recover.

Join CNBC's Healthy Returns on March 29th, where we'll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we'll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today:The shot was about 86% protective against lower respiratory tract illness with three or more symptoms, and 66.

Though the FDA views Guillain-Barre syndrome as an important potential risk, Pfizer executive Alejandra Gurtman maintained that the company did not identify any safety concerns during the trial and that the vaccine was well tolerated. Dr. David Kaslow, a senior official in the FDA's vaccine division, said safety monitoring will be "critically important" if Pfizer's RSV vaccine is approved.

Among adults of all ages hospitalized with RSV, 19% require intensive care and 4% die, according to CDC data from three seasons. Mortality is the highest among seniors.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccineFDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccineGuillain-Barre syndrome, or inflammatory neuropathy, is a disorder in which the body’s immune system mistakenly attacks the nerves.
Read more »

Pfizer, GSK face FDA panel review in race for RSV vaccinesPfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Read more »

Doctors who touted ivermectin as covid fix now pushing it for flu, RSVDoctors who touted ivermectin as covid fix now pushing it for flu, RSVFirst, the group of doctors championed ivermectin as a covid panacea. It failed to live up to the hype. Now, they’re promoting the anti-parasitic to prevent and treat the flu and RSV.
Read more »

A single injection could protect babies against RSV over winterA single injection could protect babies against RSV over winterRSV infections kill around 100,000 children each year, but now an antibody injection has proven safe and effective at reducing the risk from the disease.
Read more »

FDA authorizes combination flu-COVID test for home useFDA authorizes combination flu-COVID test for home useWhile at-home COVID tests are readily available, this is the first home test for influenza A and B, commonly known as the flu.
Read more »

FDA authorizes first at-home joint flu, COVID-19 testFDA authorizes first at-home joint flu, COVID-19 testThe Food and Drug Administration has issued an emergency use authorization for the first over-the-counter at-home test than can detect whether someone has the flu or COVID-19.
Read more »



Render Time: 2025-02-19 07:52:39